

## **Changes in the composition of AMOÉBA's Board of Directors:**

- **Appointment of Mrs Claudine VERMOT-DESROCHES and Mrs Ghislaine PINOCHET as new independent directors following the General Meeting held today**
- **Co-option of ELAIA PARTNERS by the Board of Directors, as director**

**Chassieu, June 20, 2019 - AMOÉBA** (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, announces the appointment of Claudine Vermot-Desroches and Ghislaine Pinochet as new Board members.

The General Assembly, which was held today, approved the appointment of two new directors:

- **Mrs Claudine Vermot-Desroches**, provisionally appointed by the Board of Directors on May 17, 2019, to replace Gaëtane Suzenet, for the remainder of her term of office, i.e. until the Ordinary General Meeting called to approve the financial statements for the year ending December 31, 2022.
- **Mrs Ghislaine Pinochet**, for a term of six years, i.e. until the General Meeting called to approve the financial statements for the year ending 31 December 2024.

After examining the situation of Mrs Claudine Vermot-Desroches and Mrs Ghislaine Pinochet with regard to the independence criteria defined by the MiddleNext Code to which AMOÉBA refers, the Board of Directors has qualified Mrs Vermot-Desroches and Mrs Pinochet as independent directors.

*"With the appointment of Claudine Vermot-Desroches and Ghislaine Pinochet, Amoéba is strengthening its Board of Directors to support its development and meet future diversification challenges in new applications, particularly in the areas of plant and human wound protection. I would like to thank Gaëtane Suzenet for her contribution to the Board of Directors over the past few years and welcome the arrival of our two new directors who will bring us their respective expertise in biotechnology and plant protection."* said **Fabrice PLASSON, President and CEO of AMOÉBA.**

### **Cooptation of ELAIA PARTNERS into the Board of Directors**

In addition, the Board of Directors, which met after today's General Meeting, provisionally appointed ELAIA PARTNERS as director, represented by Mr Franck LESCURE, to replace AURIGA PARTNERS, for the remainder of the term of office as representative of the Bioseeds Fund, i.e. until the Ordinary General Meeting called to approve the accounts for the financial year ending 31 December 2022, subject to ratification by the next Ordinary General Meeting.



After more than fifteen years of venture capital in Life Sciences, Franck Lescure joined Elaia as a Partner a year ago to form a life sciences team. He manages investments and sits on the boards of directors of several companies in the portfolio of the PSL Innovation Fund and, as part of a management delegation granted by Auriga Partners of Elaia, the Bioseeds fund. Sacha Loiseau and Frédéric Hammel strengthen the Life Sciences team as Venture Partners.

AMOÉBA's Board of Directors is composed of seven members, including three women and four independent directors.

#### **Claudine Vermot Desroches**

Claudine has a PhD in molecular biology and immunology from the University of Lyon and a post-doctoral fellowship from the University of Helsinki. She has more than 25 years' experience in the field of biotherapies and masters the value chain of a biomedicine covering the identification of a medical need, target validation, the generation and evaluation of biological drugs, the development of industrial bioprocesses and the creation of a patent portfolio, in immunotherapy.

Claudine has developed 4 drug candidates and owns a wide entrepreneurial experience after co-founding iDD biotech in 2008 and holding positions such as Site Manager, R&D Director and member of the Management Board Committee.

Claudine Vermot-Desroches currently heads THERAWINGS Consulting - a consulting company in therapeutic innovation, of which she is the founder.

#### **Ghislaine Pinochet**

Ghislaine Pinochet is an agricultural engineer specialized in plant protection. She has a long experience of 38 years in multinational groups (Roussel-Uclaf, Hoechst, Agrevo, Aventis, Bayer, BASF) where she has successively held various positions in Development, Business and Marketing, in France and in Europe in the field of Plant Protection and Seeds.

Since 2010, she has held various positions to establish Bayer's Seeds business in France and in Europe and has been, more particularly, in charge of the strategy for innovative projects.

#### **Elaia Partners**

Headquartered in Paris, Elaia is an independent private equity firm with more than €350m under management and invests in seed and Series A in European digital and deep tech start-ups (including life sciences). Elaia has accompanied many technological successes such as Criteo (IPO), Orchestra Networks (sold to Tibco), Sigfox, Teads (sold to Altice), Mirakl, tinyclues, Shift Technology, etc.



### **About AMOEBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPI France Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

*(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

*(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets*

*(3): BCC Research, "Markets for Advanced Wound Management Technologies", Wellesley, MA, 2017*

*(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

### **Contacts:**

#### **Amoéba**

Valérie FILIATRE

Directeur Général Adjoint

04 26 69 16 00

[valerie.filiatre@amoeba-biocide.com](mailto:valerie.filiatre@amoeba-biocide.com)

#### **Relations investisseurs**

Grégory BOSSON

Agence Calyptus

01 53 65 37 90

[gregory.bosson@calyptus.net](mailto:gregory.bosson@calyptus.net)

#### **Relations médias**

Constance LOZET

Agence Ekno

07 78 41 19 70

[constance.lozet@ekno.fr](mailto:constance.lozet@ekno.fr)

### **Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 27, 2018 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.